PATHOLOGIC STAGE IIIA CUTANEOUS MELANOMA AJCC V8
Clinical trials for PATHOLOGIC STAGE IIIA CUTANEOUS MELANOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new PATHOLOGIC STAGE IIIA CUTANEOUS MELANOMA AJCC V8 trials appear
Sign up with your email to follow new studies for PATHOLOGIC STAGE IIIA CUTANEOUS MELANOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Can a rheumatoid arthritis drug tame Immunotherapy's side effects?
Disease control OngoingThis study tests whether adding tocilizumab (a drug used for arthritis) to standard immunotherapy can reduce severe side effects in people with advanced melanoma, lung cancer, or bladder cancer. About 35 participants will receive all three drugs. The goal is to see if the combina…
Matched conditions: PATHOLOGIC STAGE IIIA CUTANEOUS MELANOMA AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 23, 2026 11:58 UTC
-
New hope for kidney transplant patients with cancer: drug combo aims to fight tumors without losing the donated kidney
Disease control OngoingThis early-stage study tests whether a mix of three drugs—tacrolimus, nivolumab, and ipilimumab—can shrink or control certain skin cancers in people who have had a kidney transplant. The main goal is to see if the cancer responds without causing the body to reject the transplante…
Matched conditions: PATHOLOGIC STAGE IIIA CUTANEOUS MELANOMA AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 01, 2026 18:04 UTC
-
Cholesterol drug may block melanoma spread in High-Risk patients
Prevention OngoingThis study tests whether atorvastatin, a widely used cholesterol medication, can prevent melanoma from returning or spreading in people who have had high-risk melanoma surgically removed. About 150 adults with stage IIA, IIB, or IIIA melanoma will receive either atorvastatin or a…
Matched conditions: PATHOLOGIC STAGE IIIA CUTANEOUS MELANOMA AJCC V8
Phase: PHASE2 • Sponsor: OHSU Knight Cancer Institute • Aim: Prevention
Last updated Jun 01, 2026 17:55 UTC
-
Melanoma survivors: can we predict immunotherapy side effects?
Knowledge-focused OngoingThis study follows 126 melanoma survivors who are receiving immunotherapy after surgery to prevent cancer from coming back. Researchers track side effects and quality of life over two years, and collect blood samples to look for biomarkers that might predict who will have problem…
Matched conditions: PATHOLOGIC STAGE IIIA CUTANEOUS MELANOMA AJCC V8
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 23, 2026 20:33 UTC
-
Facebook groups aim to boost skin exams in young melanoma families
Knowledge-focused OngoingThis study tests whether a private Facebook group can help young adults (ages 18-39) diagnosed with early-stage melanoma and their close family members do more thorough skin checks and use better sun protection. About 1,160 participants will join either a melanoma-focused or a ge…
Matched conditions: PATHOLOGIC STAGE IIIA CUTANEOUS MELANOMA AJCC V8
Phase: NA • Sponsor: Rutgers, The State University of New Jersey • Aim: Knowledge-focused
Last updated Jun 18, 2026 11:52 UTC